Informed Consent Form for Patients Taking Chemotherapy

Size: px
Start display at page:

Download "Informed Consent Form for Patients Taking Chemotherapy"

Transcription

1 Patient s Name-Surname: Gender: F... M... Patient ID No: Date of Birth: Father s Name: ID No: Dear Patient/Relative of Patient, It is your incontestable right to obtain information regarding your medical condition and illness, and all sorts of medical treatments, operations, and diagnosis procedures recommended to you. Also, after receiving thorough information about the procedures, benefits and possible side effects of medical treatments and operations, it is at your own consent to allow or not to allow medical practices to be carried out. The fundamental aim of this statement is assisting and illuminating you in taking accurate decisions regarding your health. If you wish so, all sorts of documents regarding your health and treatment can be delivered to you or any relative of yours. This form is prepared as a supportive document for informing you of the risks and alternative treatment methods related to the treatment/medical application being planned to be practiced by the doctor who has been consulting to you. Please read this document carefully and sign this informed consent form after all your doubts and queries, regarding the application, have been cleared by the doctor. 1. PRE-DIAGNOSIS/DIAGNOSIS:... GENERAL INFORMATION ABOUT YOUR ILNESS: What is Chemotherapy? Chemotherapy refers to medical treatment by using drugs to kill the tumorous cells. It can be used both for destroying cancerous cells that are diagnosed through medical consultation or various diagnosis methods, and for destroying the microscopic remains of tumours that were already removed by an operation. In this way, it is aimed to entirely cure the disease if possible, if this is not possible, to extend the living period and ensure quality of life and reduce the level of symptoms as much as possible. The superiority of chemotherapy when it is compared to radiotherapy and operational treatments is that when it is applied it affects all the tumorous cells all around the body at the same time. In this regard, chemotherapy is a systemic treatment. Tumorous cells differ from healthy cells by multiplying themselves much faster than others, following different metabolic ways for growing up and proliferating, needing certain chemicals called growing up factors, having different molecules on their surfaces, becoming dependant to development of new veins, self-protecting themselves from aging and dying from natural courses of aging, and repairing some constituents that are essential for maintaining their living conditions. Chemotherapy drugs are used targeting to destroy all or some aspects of these features of tumorous cells, on the other hand, attempting to protect the healthy cells as much as possible. However, it should be borne in mind that cancerous cells are originated from normal cells, and therefore there are many similarities between the healthy cells and cancerous cells. This means that chemotherapy drugs can harm the healthy cells as well, and therefore cause some side effects, and these side effects may be very serious. Nevertheless, when the severity of the illness is taken into consideration, such side effects are to be considered acceptable and reasonable. Employing specialist doctors and staff in this kind of treatment makes it possible to keep the side effects of chemotherapy treatment at minimum levels. KTR_BF01_RV00 1/

2 2. RECOMMENDED CHEMOTHREAPY:... The document of chemotherapy treatment to be carried out must be attached to this informed consent form. 3. TREATMENT AREA: Right Left Both sides Level:. 4. COURSE OF ANAESTHESIA: Yes No Information was provided about the course of anaesthesia by the anaesthetist, and information was given that an approval will be obtained after the information was provided by the anaesthetist. 5. USE OF BLOOD AND BLOOD PRODUCTS: Yes No Information was given on if blood products are to be used and an approval of the patient is necessary for this course. 6. RISKS OF RECOMMENDED MEDICAL TREATMENT/APPLICATION Are there any side effects of chemotherapy? Decrease in number of blood cells: Keeping the cells existing in blood at a certain level is possible by fast and continuous segmentation of certain cells. Three types of blood cells are important in regards to chemotherapy course; white cells are important especially in increasing the immune system of the body against the infections. Thrombocytes (blood platelets) take responsibility to stop bleeding when the veins are harmed and bleeding starts. Red cells transfer oxygen to tissues. Decrease in the number of first two groups of cells cause bleeding risks, and decrease in the number of red cells is called anaemia. These problems usually are encountered at a non-significant level, however, if severe conditions are to be encountered then they taken under control by giving antibiotics, thrombocytes and red cell transplantation. However, although they happen rarely, fatal bleedings and infections may occur and unless they are cured appropriately they lead to mortalities. Thus, before and after chemotherapy courses blood cell counts must be done within certain periods and results must be given to doctors and/or nurses. Nausea and Vomiting: Unless they are given without taking any precautions, the chemotherapy drugs cause nausea and vomiting up to some extend. However, today drugs preventing nausea and vomiting are available and such drugs corresponding to the level of nausea and vomiting caused by the dosage of chemotherapy are used certainly before the chemotherapy course is given to you. This side effect of chemotherapy can start right from the very beginning of chemotherapy course and may last for a couple of days, in such cases you will be recommended to take some drugs to prevent nausea and vomiting after the chemotherapy course. Today even the most severe vomiting and nausea incidents may be taken under control 70-80% due to the medical treatments with developed drugs. Hair Loss: Cells of hair roots are fast growing cells, thus they are directly affected from most of the chemotherapy drugs and, as a result of this, patient s hair get thinner or patient may suffer from total hair loss. This sort of side effects is generally impermanent and as soon as the chemotherapy sessions are over the hair starts to grow up. So, what is important during treatment is undergoing the chemotherapy sessions without encountering serious health problems. To overcome such a cosmetic problem, the patient may wear a wig or change the hair style. KTR_BF01_RV00 2/

3 Other Skin and Nail Problems: Some chemotherapy drugs cause loss of hair at the other parts of body, skin drying, and changes of colour of pigments. White lines may appear on nails during the repeating courses of chemotherapy, however such physical changes are entirely harmless. Some drugs such as Taksoter (Dosetaksel) may make nails fragile and fractures may appear on nails, and nails may be dislocated from their places. Such drugs such as Kapesitabin may cause rash, cracks, and swelling in palms and soles which may be painful skin problems. Should you feel that such health problems started during your treatment, you must immediately inform your doctor. Side Effects on Oral (mouth) Cavity, Stomach and Intestinal System: Our digestive system, being comprised of mouth, stomach and intestines is formed by cells that are constantly segmenting and thus constantly regenerating. Chemotherapy can destroy the nature of these cells and this may cause to health problems such as aphtha, aphthaous ulcers, diarrhoea, difficulty in swallowing food and drinks, and stomach ache. Such health problems are usually temporary and can be recovered through supportive care. However, you must contact to your doctor as soon as you are aware of such problems. Side Effects on Genital System and Health: Some drugs may cause menstrual irregularity or menopause, and such effects may be permanent. However, in the cases of some tumours, menopause may be preferred due to some medical reasons. When they are used in certain doses, some drugs may cause temporary or permanent infertility in men and women. Thus, if you wish to have children after the treatment period, you must discuss this issue with your doctor before your treatment starts. Using chemotherapy drugs on pregnant or nursing mothers can cause very serious health problems on their children. If you are in such a medical condition you must immediately inform your doctor, and if you have even the slightest suspicion about pregnancy, you must immediately carry out pregnancy tests and ensure that you are not pregnant. Women must not be pregnant during chemotherapy courses. If necessary, along with the measures of contraception, further precautions such as using condoms must be taken in order to prevent the transfer of remains of chemotherapy drugs. Side Effects on Kidneys and Urinary Tract: As a general rule, sufficient amount of liquid must be taken during chemotherapy. Taking sufficient liquid helps to remove the remains of dead cells and excess chemotherapy drugs. In addition, side effects of drugs, such as cisplatine and metotreksat- which can directly harm the kidneys, can also be prevented by sufficient liquid intake. Furthermore, some drugs, such as ifosfamid and siclophosphamid can cause bleeding in the urinary tract. To prevent this, again, sufficient amount of liquid is taken and some preventive medicine is used. If your intake of liquid is insufficient because of nausea-vomiting or because of the narrowness caused in the gastrointestinal tact due to a tumour, or in fact, you notice a decrease in the amount of your urination, you should contact your doctor promptly; otherwise, if this situation is not treated, it could lead to permanent damage in the kidneys and in some rare case, it can be fatal. Allergic Reactions: Theoretically all drugs, and so forth chemotherapy drugs can lead to allergic reactions. These generally appear in the form of contractions or rush, and these reactions, which appear in sensitive individuals, may sometimes be life threatening. In treatments requiring use of paclitaxel, rituximab, bleomycin, L-asparaginase, which are known to cause a higher risk of allergic reactions, protective treatment before the major treatment are applied KTR_BF01_RV00 3/

4 and patients are kept under observation. If you are aware of having any allergic reactions to any type of drugs, be sure to inform your doctor about it. Side Effects on the Heart: Some drugs such as; Adriamycin, epirubicin, idarubicin, novantrone, a high dose of cylophosphamide, fluorouracil could have serious side effects on the heart. Preceding treatment with the above mentioned drugs, a detailed evaluation of the heart health must be made and periodical controls of the heart must be carried out throughout the treatment process. In addition, the dose of the drugs being used should be kept below a certain level. Furthermore, radiotherapy and certain drugs should be avoided, as they have a tendency to increase the side effects of the chemotherapy. Through these precautions, the damage of the heart is kept at minimum and in fact they lead to complete avoidance of any side effects on the heart. If you are aware of any kind of health problems with your heart or suffer from any kind of heart problem during the chemotherapy treatment, be sure to inform your doctor about it. This could mean a change in the drugs being used, as a part of the treatment. Side Effects on the Nerve System: The use of drugs during the chemotherapy, a feeling of restlessness, nerviness, sleeplessness or sleepiness could be seen as side effects. However, these symptoms are usually not dependent on only the drugs being used. Certain drugs, such as ifosfamid, in very rare occasions lead to the loss of consciousness or epilepsy attacks. Drugs such as; onkovin, oxaliplatin cisplatin, begin showing symptoms by the numbness in fingertips, and if precautions are not taken, could lead to a stronger symptom of loss of strength, which also leads to damage on the neural transmissions. Specially, the use of the cisplatin drug could lead to permanent damage on the sense of hearing. Your doctor has noted the side effects of drugs, which are suggested to you, in the space provided below. (These side effects are not mentioned above.) Make sure you have read them thoroughly. The summary provided above is related to the most important side effects which may be encountered during the chemotherapy process. However, bare in mind that there are many drugs used in chemotherapy and each drug shows individual differences. In this respect, do not expect the side effects to be unavoidable. Generally, patients suffer from a couple of light-medium strength side effects, majority of which are able to be overcome with the help of supportive treatments. The reason why the side effects are being explained in detail is to make sure you receive your treatment with a higher understanding and so that you can contact your doctor as soon as you feel any disnormality. Please make sure you read the explanations provided thoroughly and be sure to be clear about them. Do not hesitate to inquire your doctor and/or nurse of any questions that may come into mind. After signing the first page of this form as a decision of accepting the treatment proposed to you, details of your treatment will be provided to you (i.e. which drugs will be used by which application methods and by which intervals, and so on), side effects and how they will be observed will be explained and a description will be provided regarding which examinations will be required. We would like to thank you for your attention and we wish you a successful treatment process. KTR_BF01_RV00 4/

5 7. The Probability of Success of the Suggested Medical Application The success of the medical application depends on the degree of the illness, the reason behind it and the response one s body gives to the treatment. 8. Possible Alternative Medical Applications As far as radiotherapy is concerned, there are no other alternatives for this treatment, as a treatment for your illness at this stage. 9. Potential Benefits from the Suggested Medical Application It is to get the illness under-control/ treated. 10. Issues about which the Patient Needs to be Cautious About During Remission and Prior to Medical Application Preparation Prior to Chemotherapy: If the patient s consciousness and age is appropriate, your doctor will consult you on details of the process prior to the application. Please make sure to provide information of the following to your doctor: medical problems, medication(s) being used, if present; bleeding problems, and/or allergic reactions to certain things (such asdrugs, latex gloves, plasters) or any other illnesses. What will happen after the Treatment has been completed? Certain effects of the chemotherapy might continue for a couple of weeks after completing the treatment. Remission and proper nutrition at this stage holds great importance. Your doctor will continue to observe your condition through regular appointments. You have the opportunity to move your appointments forward, if you have any worries or in need of inquiry about your condition. You will be informed, through the epicrisis report, on the type of application used by the radiotherapy doctor. Please bear in mind that this report may not be an answer to all possible questions and do not hesitate to consult your doctor on issues which you need to be enlightened on. Your doctor will no be able to enlighten you on these issues unless you consult them. 11. Possible Results of Refusing the Suggested Medical Applications Your child s/patient s has been pathologically diagnosed and staging of the illness have been completed. Not applying radiotherapy, which has no other alternative treatment(s) in our day, and/or not applying chemotherapy to your patient may mean; not taking the illness under control. It is necessary to follow the suggested medical treatment. Scope of the Suggested Treatment and Consent I have been verbally informed about the suggested treatment in detail and have read information regarding the process. All my relevant questions have been answered to. I allow blood and blood product procedures in unexpected and emergency situations. The doctor has informed me of additional medical applications which may be come across as predicted from before and/or beyond prediction during the medical application process. I accept further medical attempts, which my doctor may need to follow, so as to prevent serious health problems and as a necessity to save my life. As for the medical attempts mentioned above, I am aware that the following may be used for my treatment: x-ray, endoscopy, ultrasonography, scintigraphy, computerized tomography, magnetic resonance, and alike. I am also aware that the use of some of these devices may lead to negative effects on my health and I accept them to be used if found necessary during my treatment process. KTR_BF01_RV00 5/

6 I am informed an average cost of the additional medical attempts which may be necessary. As a part of health application procedures, I authorize and consent tissue(s)/organ(s) which may be removed and images of these or tissue/cell culture to be used in scientific research and to be stored or disposed of as appropriate. I.., have read and understand the contents of this form and I agree to the necessary applications to be made by Near East University Hospital doctors under the authorization, observation and direction of Dr.throughout the treatment process. With an open consciousness, I accept and allow all of the mentioned above and also care of other working staff of health. I consent all types of drugs, examinations and medical attempts which are necessary as part of my treatment process. Signature: Date: Time: If the consent has been provided by the legal representative of the patient; Degree of Legal Representative: The Patient is unconscious The Patient is below the age of 18 The Patient has not got legal right to provide approval Emergency Witness (if applicable, someone other than the staff of the hospital); Name-Surname: Signature: Date: Time: Statement of Health Professional; Name-Surname: Signature: Date: Time: Statement of the Interpreter (if needed); Name-Surname: Signature: Date: Time: This part is to be signed by: Patients himself/herself if over the age of 18. Patients who are between the ages of are to sign this alongside his/her legal representative. Patients with closed consciousness, below the age of 15, in emergency condition and those who have not the ability to decide will be represented by their legal representative and thus, he/she will sign this form on their behalf. KTR_BF01_RV00 6/

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: FEC-P PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP: MALE

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-EC PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: BEP (5 day) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Oxaliplatin- Fluorouracil (FOLFOX) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-Oxaliplatin- Fluorouracil (FLOT) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine- Carboplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Carboplatin-Etoposide PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Nintedanib-Docetaxel PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

INFORMED CONSENT FORM FOR SEPTOPLASTY(OPERATION FOR THE DEVIATED NASAL SEPTUM)

INFORMED CONSENT FORM FOR SEPTOPLASTY(OPERATION FOR THE DEVIATED NASAL SEPTUM) Patient Name-Surname: Sex: F M Patient No: Date of Birth: Father s Name: ID Card No: Dear Patient / Guardian It is your incontestable right to be informed about all medical/surgical procedures suggested

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cisplatin- Capecitabine- Trastuzumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Axitinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL

Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL Patient s surname/family name Patient s first names Date of birth

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pazopanib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Dabrafenib-Trametinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Ponatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

INFORMED CONSENT FORM FOR TONSILLECTOMY, ADENOTONSILLECTOMY, PERYTONSILLARY ABCESS

INFORMED CONSENT FORM FOR TONSILLECTOMY, ADENOTONSILLECTOMY, PERYTONSILLARY ABCESS Patient Name-Surname: Sex: F M Patient No: Date of Birth: Father s Name: ID Card No: Dear Patient / Guardian It is your incontestable right to be informed about all medical/surgical procedures suggested

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pembrolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names. Patient identifier/label: Page 1 of 6 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Irinotecan- Capecitabine (CAPIRI) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS Patient s surname/family name Patient s first names Date of birth Hospital

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB. Patient s first names. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Atezolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Sunitinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth

PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth Page 1 of 6 FORM FERRERI / IELSG PROTOCOL Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Everolimus PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Niraparib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

Eloxatin Oxaliplatin concentrated solution for injection

Eloxatin Oxaliplatin concentrated solution for injection Eloxatin Oxaliplatin concentrated solution for injection Consumer Medicine Information Please read this leaflet before you are given this medicine. What is in this leaflet This leaflet answers some common

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE)

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE) Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

Edinburgh Cancer Centre, Western General Hospital. Understanding Epirubicin, Oxaliplatin & 5-Fluorouracil Chemotherapy (EOF)

Edinburgh Cancer Centre, Western General Hospital. Understanding Epirubicin, Oxaliplatin & 5-Fluorouracil Chemotherapy (EOF) Introduction This booklet has been designed to help you and your family understand more about the chemotherapy that you are about to have as treatment for your cancer. If you need more information or have

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Bevacizumab + Chemotherapy PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

Haematology. C = Cyclophosphamide (pronounced sigh clo fos fa mide)

Haematology. C = Cyclophosphamide (pronounced sigh clo fos fa mide) Haematology CEPP Chemotherapy This information is about CEPP chemotherapy, which is a treatment for Lymphoma. Lymphoma is a cancer of the lymphatic system - a network of glands in the body that helps to

More information

Consumer Medicine Information March 2009

Consumer Medicine Information March 2009 March 2009 50 (oxaliplatin 50mg power for injection vial) 100 (oxaliplatin 100mg power for injection vial) What is in this leaflet? This leaflet answers some common questions about Powder for injection.

More information

VIDE. Vincristine given via intravenous (IV) infusion over 10 minutes Etoposide & doxorubicin given together via IV infusion over 4 hours

VIDE. Vincristine given via intravenous (IV) infusion over 10 minutes Etoposide & doxorubicin given together via IV infusion over 4 hours VIDE VIDE This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may

More information

Department of Clinical Haematology. Chemotherapy. Information for patients. Page 1 of 12

Department of Clinical Haematology. Chemotherapy. Information for patients. Page 1 of 12 Department of Clinical Haematology Chemotherapy Information for patients Page 1 of 12 You may find this booklet helpful if you or someone close to you is going to have chemotherapy. It explains: what chemotherapy

More information

X-Plain Chemotherapy Reference Summary

X-Plain Chemotherapy Reference Summary X-Plain Chemotherapy Reference Summary Introduction Chemotherapy is a common treatment for a variety of cancers. It has been proven to be both safe and effective. Patients should, however, learn about

More information

Haematology. R - CEPP Chemotherapy

Haematology. R - CEPP Chemotherapy Haematology R - CEPP Chemotherapy This information is about R-CEPP chemotherapy, which is a treatment for Lymphoma. Lymphoma is a cancer of the lymphatic system a network of glands in the body that helps

More information

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB. Patient s first names.

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB. Patient s first names. Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other

More information

Doxorubicin & Ifosfamide

Doxorubicin & Ifosfamide Doxorubicin & Ifosfamide Doxorubicin & Ifosfamide This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of

More information

Upper Gastrointestinal Endoscopy -Open Access

Upper Gastrointestinal Endoscopy -Open Access Upper Gastrointestinal Endoscopy - Open Access Facility:... A. INTERPRETER / CULTURAL NEEDS An Interpreter Service is required? Yes No If Yes, is a qualified Interpreter present? Yes No A Cultural Support

More information

Haematology. The other 2 drugs, folinic acid and GCSF, help to reduce the side effects of the treatment.

Haematology. The other 2 drugs, folinic acid and GCSF, help to reduce the side effects of the treatment. Haematology CODOX-M Chemotherapy This information is about CODOX-M chemotherapy, which is a treatment for Burkitts Lymphoma. Lymphoma is a cancer of the lymphatic system - a network of glands in the body

More information

Stretching of the corners of the mouth that may lead to cracking or bruising.

Stretching of the corners of the mouth that may lead to cracking or bruising. INFORMED CONSENT FOR REMOVAL OF CYST OR TUMOR Practice Administrator 9450 E Ironwood Square Dr. Scottsdale, AZ 85258 Phone: (480) 551-0581 Fax: (480) 551-0585 www.anewbeautifulyou.com Patient s Name Please

More information

For the Patient: ACTW Other names: BRAJACTW

For the Patient: ACTW Other names: BRAJACTW For the Patient: ACTW Other names: BRAJACTW A Doxorubicin (ADRIAMYCIN ) C Cyclophosphamide T Paclitaxel (TAXOL ) weekly Uses: BRAJACTW is a drug treatment given after breast cancer surgery (called adjuvant

More information

Paclitaxel (Taxol) and carboplatin

Paclitaxel (Taxol) and carboplatin Paclitaxel (Taxol) and carboplatin Paclitaxel (Taxol) and carboplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may

More information

For the Patient: LUAVPG (Carboplatin Option)

For the Patient: LUAVPG (Carboplatin Option) For the Patient: LUAVPG (Carboplatin Option) Other Names: Treatment of Advanced n-small Cell Lung Cancer with Carboplatin and Gemcitabine LU = LUng AV = AdVanced PG = CarboPlatin, Gemcitabine ABOUT THIS

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide

PACKAGE LEAFLET: INFORMATION FOR THE USER. ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide PACKAGE LEAFLET: INFORMATION FOR THE USER ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide Read all of this leaflet carefully before you start using this medicine because it contains

More information

Your treatment. 240 BEP 3 Days Page 1 of 6

Your treatment. 240 BEP 3 Days Page 1 of 6 BEP - 3 Days BEP - 3 Days This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back,

More information

VDC IE. Your treatment You will have 14 cycles of VDC IE given every 2 to 3 weeks.

VDC IE. Your treatment You will have 14 cycles of VDC IE given every 2 to 3 weeks. VDC IE VDC IE This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others

More information

For the Patient: Neoadjuvant therapy for locally advanced breast cancer using weekly paclitaxel followed by doxorubicin and cyclophosphamide

For the Patient: Neoadjuvant therapy for locally advanced breast cancer using weekly paclitaxel followed by doxorubicin and cyclophosphamide For the Patient: Neoadjuvant therapy for locally advanced breast cancer using weekly paclitaxel followed by doxorubicin and cyclophosphamide Other names: BRLATWAC BR Breast LA Locally Advanced T A C Paclitaxel

More information

TC: Docetaxel and Cyclophosphamide

TC: Docetaxel and Cyclophosphamide PATIENT EDUCATION patienteducation.osumc.edu What is TC? It is the short name for the drugs used for this chemotherapy treatment. The two drugs you will receive during this treatment are Docetaxel (Taxotere

More information

Patient information/declaration of consent for ERCP (imaging of the bile ducts and pancreas with a contrast substance)

Patient information/declaration of consent for ERCP (imaging of the bile ducts and pancreas with a contrast substance) - 1 - Patient information/declaration of consent for ERCP (imaging of the bile ducts and pancreas with a contrast substance) Declaration of informed consent provided by: Date: Dear Patient, Please be so

More information

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions Capecitabine Other Names: Xeloda About This Drug Capecitabine is used to treat cancer. It is given orally (by mouth). Possible Side Effects Tired and weakness Loose bowel movements (diarrhea) Nausea and

More information

IMIPENEM+CILASTATIN RBX

IMIPENEM+CILASTATIN RBX IMIPENEM+CILASTATIN RBX imipenem/cilastatin sodium 500 mg/500 mg Powder for Solution for Infusion What is in this leaflet This leaflet answers some common questions about IMIPENEM+CILASTATIN RBX. It does

More information

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth.

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth. Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Zoledronic acid PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate

PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read

More information

Fractured neck of femur

Fractured neck of femur PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a fractured neck of femur? A healthy hip joint is vital to normal walking

More information

PRE-SEDATION RECORD PHYSICIAN S ASSESSMENT

PRE-SEDATION RECORD PHYSICIAN S ASSESSMENT PRE-SEDATION RECORD PHYSICIAN S ASSESSMENT Dear Doctor, Your patient is scheduled for dental treatment under intravenous sedation. Please complete this history and physical examination form and return

More information

If you have any concerns about being given this medicine, ask your doctor or pharmacist.

If you have any concerns about being given this medicine, ask your doctor or pharmacist. PRIMAXIN imipenem/cilastatin sodium 500 mg/500 mg Vial for injection What is in this leaflet This leaflet answers some common questions about PRIMAXIN. It does not contain all the available information.

More information

Paclitaxel and Carboplatin

Paclitaxel and Carboplatin PATIENT EDUCATION patienteducation.osumc.edu What is Paclitaxel (pak-li-tax-el) and how does it work? Paclitaxel is a chemotherapy drug known as an anti-microtubule inhibitor. Another name for this drug

More information

Gemcitabine and Cisplatin (urology)

Gemcitabine and Cisplatin (urology) Gemcitabine and Cisplatin Gemcitabine and Cisplatin (urology) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce

More information

Oral cyclophosphamide in ovarian cancer

Oral cyclophosphamide in ovarian cancer Oral cyclophosphamide in ovarian cancer Oral cyclophosphamide in ovarian cancer This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy

More information

Myeloma Haematology and Transplant Unit CTD1

Myeloma Haematology and Transplant Unit CTD1 CTD1 Myeloma Haematology and Transplant Unit CTD1 This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of

More information

HERNOVIR 200 mg tablets

HERNOVIR 200 mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER HERNOVIR 200 mg tablets ACICLOVIR This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

For the Patient: CAP. Capecitabine. Uses:

For the Patient: CAP. Capecitabine. Uses: For the Patient: CAP Other names: BRAVCAP CAP Capecitabine Uses: BRAVCAP is an oral chemotherapy drug treatment plan, given as therapy for metastatic breast cancer, in the hope of destroying breast cancer

More information

Laparoscopic radical nephrectomy

Laparoscopic radical nephrectomy PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a laparoscopic radical nephrectomy? This is a procedure which involves removal

More information

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you. New Zealand Consumer Medicine Information MABTHERA SC Rituximab 1400 mg solution for subcutaneous injection for non-hodgkin s Lymphoma and 1600mg solution for subcutaneous injection for chronic lymphocytic

More information

PRIMAXIN Imipenem/Cilastatin sodium

PRIMAXIN Imipenem/Cilastatin sodium PRIMAXIN Imipenem/Cilastatin sodium Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about PRIMAXIN. It does not contain all the available information. It

More information

Weekly standard dose. Paclitaxel (Taxol) and carboplatin

Weekly standard dose. Paclitaxel (Taxol) and carboplatin paclitaxel (taxol) and carboplatin Paclitaxel (Taxol) and carboplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may

More information

TCH: Docetaxel, Carboplatin and Trastuzumab

TCH: Docetaxel, Carboplatin and Trastuzumab PATIENT EDUCATION patienteducation.osumc.edu TCH: Docetaxel, Carboplatin and Trastuzumab What is TCH? It is the short name for the drugs used for this chemotherapy treatment. The three drugs you will receive

More information

Radiotherapy to the bladder

Radiotherapy to the bladder Radiotherapy to the bladder Information for patients The aim of this leaflet is to provide you with information about the use of external beam radiotherapy in treating bladder cancer, including details

More information

Arthroscopic subacromial decompression (ASD) with or without AC joint removal

Arthroscopic subacromial decompression (ASD) with or without AC joint removal PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an ASD? Arthroscopic: Using a camera and specially designed instruments we

More information

Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer)

Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer) Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer) The possible benefits of treatment vary; for some people chemotherapy may reduce the

More information

For the Patient: GUBEP

For the Patient: GUBEP For the Patient: GUBEP Other Names: Treatment with Bleomycin, Etoposide, Cisplatin for Germ Cell Cancers. GU = GenitoUrinary (tumor group) B = Bleomycin E = Etoposide P = Platin (Cisplatin) ABOUT THIS

More information

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Carbamazepine For the Treatment of Pain This information is not intended to replace your doctor s

More information

Leukemia. There are different types of leukemia and several treatment options for each type.

Leukemia. There are different types of leukemia and several treatment options for each type. Leukemia Introduction Leukemia is the name of a group of cancers of the blood cells. Hundreds of thousands of people worldwide are diagnosed with leukemia each year. There are different types of leukemia

More information

Cisplatin and gemcitabine (GI)

Cisplatin and gemcitabine (GI) Cisplatin and gemcitabine (GI) Cisplatin and gemcitabine (GI) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce

More information

Cisplatin and Capecitabine

Cisplatin and Capecitabine Cisplatin and Capecitabine Cisplatin and Capecitabine This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk

More information

Fitting of an Intrauterine Device (IUD)

Fitting of an Intrauterine Device (IUD) PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an IUD? An IUD is a small T-shaped plastic and copper device that is put into

More information

Information for patients who need to be operated under anaesthesia or who need other therapeutic or diagnostic procedures under anaesthesia

Information for patients who need to be operated under anaesthesia or who need other therapeutic or diagnostic procedures under anaesthesia Information for patients who need to be operated under anaesthesia or who need other therapeutic or diagnostic procedures under anaesthesia Dear Sir/Madam, It is our wish and obligation to explain to you

More information

How is primary breast cancer treated? This booklet is for anyone who has primary breast cancer and wants to know more about how it is treated.

How is primary breast cancer treated? This booklet is for anyone who has primary breast cancer and wants to know more about how it is treated. How is primary breast cancer treated? This booklet is for anyone who has primary breast cancer and wants to know more about how it is treated. How is primary breast cancer treated? Part 1 the treatment

More information

About general anaesthesia Day Surgery Unit Patient Information Leaflet

About general anaesthesia Day Surgery Unit Patient Information Leaflet About general anaesthesia Day Surgery Unit Patient Information Leaflet Originator: Nahla Farid - Consultant Anaesthetist Date: November 2011 Version: 1 Date for Review: November 2014 DGOH Ref No: DGOH/PIL/00560

More information

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased

More information

MEDICAL AND PERSONAL HISTORY

MEDICAL AND PERSONAL HISTORY MEDICAL AND PERSONAL HISTORY Last First MI Today s Date Name Age Mr. Mrs Ms Dr Address Home Phone City, State, Zip Work Phone Sex: M F Patient SS# Cell Phone Date of Birth / / Responsible Party Referring

More information

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

Parathyroidectomy. Surgery for Parathyroid Problems

Parathyroidectomy. Surgery for Parathyroid Problems Parathyroidectomy Surgery for Parathyroid Problems Why You Need Parathyroid Surgery Has your doctor just recommended that you have parathyroid surgery? If so, you likely have many questions. What are the

More information

Mitomycin C given by injection into a vein. Cisplatin and hydration (fluids) via a drip over 6 or 18 hours.

Mitomycin C given by injection into a vein. Cisplatin and hydration (fluids) via a drip over 6 or 18 hours. Cisplatin & Mitomycin C Cisplatin & Mitomycin C This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the

More information

AUGMENTIN is also used to prevent infection from major surgery.

AUGMENTIN is also used to prevent infection from major surgery. Injection Potassium clavulanate/amoxicillin sodium equivalent to 100 mg clavulanic acid/500 mg amoxicillin Potassium clavulanate/amoxicillin sodium equivalent to 200 mg clavulanic acid/1 g amoxicillin

More information

INFORMED CONSENT FOR HYDRATION THERAPY SERVICES AND ARBITRATION AGREEMENT

INFORMED CONSENT FOR HYDRATION THERAPY SERVICES AND ARBITRATION AGREEMENT INFORMED CONSENT FOR HYDRATION THERAPY SERVICES AND ARBITRATION AGREEMENT Name: Address: City/State/Zip Code: _ Telephone No.: Gender: Date of Birth: (VALID IDENTIFICATION REQUIRED) Emergency Contact Information:

More information

Gemcitabine and carboplatin (Breast)

Gemcitabine and carboplatin (Breast) Gemcitabine and carboplatin (Breast) Gemcitabine and carboplatin (Breast) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy

More information

Pentostatin (Nipent )

Pentostatin (Nipent ) Pentostatin (Nipent ) Pentostatin (Nipent ) This leaflet is offered as a guide to you and your family. Your treatment will be fully explained by your doctor or nurse, who will be happy to answer any questions.

More information

Myeloma Haematology and Transplant Unit

Myeloma Haematology and Transplant Unit BCD Myeloma Haematology and Transplant Unit BCD This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the

More information

Sorafenib (Nexavar ) ( sor-af-e-nib )

Sorafenib (Nexavar ) ( sor-af-e-nib ) Sorafenib (Nexavar ) ( sor-af-e-nib ) How the drug is given: by mouth Purpose: To stop the growth of cancer cells in kidney cancer, liver cancer, and other cancers How to take the drug by mouth Take on

More information

For the Patient: ULUAVPMB

For the Patient: ULUAVPMB For the Patient: ULUAVPMB Other Names: Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab U = Undesignated (requires special approval) LU = LUng AV = AdVanced PMB = PeMBrolizumab ABOUT

More information